Essai Clinique

Généré le 28 avr. 2025 à partir de

Titre	Extended Access of Momelotinib for Subjects With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Protocole ID	GS-US-352-4365
ClinicalTrials.gov ID	NCT03441113
Type(s) de cancer	Syndrome myélodysplasique
Phase	Phase II
Stade	Myélofibrose
Type étude	Traitement
Médicament	Momelotinib
Institution	CENTRE UNIVERSITAIRE DE SANTE MCGILL SITE GLEN 1001 boul. Décarie , Montréal, QC, H4A 3J1
Ville	
Investigateur principal	Dr Jonathan How
Coordonnateur	Judit Kokai 438-888-1582
Statut	Fermé
But étude	The primary objective of this study is to provide extended access of momelotinib (MMB) in participants with primary myelofibrosis (PMF) or post-polycythemia vera or post-essential thrombocythemia myelofibrosis (Post-PV/ET MF) enrolled in studies GS-US-352-0101 (NCT01969838), GS-352-1214 (NCT02101268), GS-US-352-1154 (NCT02124746), who are currently receiving treatment with MMB (available as 100 mg, 150 mg and 200 mg tablets) and have not experienced progression of disease.
Critères d'éligibilité	• Currently enrolled in Studies GS-US-352-0101, GS-US-352-1214, or GS-US-352-1154 • Able to comprehend and willing to sign the informed consent form
Critères d'exclusion	• Known hypersensitivity to MMB, its metabolites, or formulation excipients